NasdaqOn RegSHO · 5 days in a row
$2.32▲ 1.75%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.7MShares out 2.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
26- 1d agoAfter-hours26.10.24 05:308-KKey event#●●●
Alaunos Therapeutics, Inc.Bullish
Alaunos Therapeutics has regained compliance with the Nasdaq minimum stockholders' equity requirement of $2.5 million following the completion of a private placement on October 14. Consequently, Nasdaq has closed the delisting matter, cancelled the hearing scheduled for November 10, and confirmed the continued listing of the company's common stock.…more
$2.32+1.75%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 05:308-KKey event
Alaunos Therapeutics, Inc.
Alaunos Therapeutics announced that it has regained compliance with Nasdaq's stockholders' equity requirement following the completion of its acquisition of Velaris Therapeutics and a $350 million financing. By securing a waiver for cash settlement rights on certain preferred shares, the company believes it has met the listing standards and expects the previously scheduled Nasdaq hearing to be cancelled.…more
$2.32+1.75%vs prev closeView filingShare - 10.15After-hours26.10.16 08:55SCHEDULE 13D/AOwnership
Alaunos Therapeutics, Inc.
A Schedule 13D/A filing for Alaunos Therapeutics, Inc. has been submitted. Robert W. Postma is identified as the reporting person, and the filing details changes in beneficial ownership.…more
$2.32+1.75%vs prev closeView filingShare
25 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Regular26.10.14 02:20Bullish#●●●#●●●#●●●
Alaunos Therapeutics Surges on Velaris Acquisition and $350M Capital Raise…more
Alaunos Therapeutics shares soared following its acquisition of Velaris Therapeutics and a concurrent $350 million private placement. This capital infusion provides the company with sufficient runway through 2029 to advance its pulmonary arterial hypertension treatment pipeline.…more
$2.32+1.75%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.13Regular26.10.13 23:31
●●●●●●●● ●●●●● ●●●●●●
Alaunos Therapeutics has completed the acquisition of Velaris Therapeutics alongside a $350 million private placement. The transaction involves significant share issuance, which will result in dilution for existing shareholders.…more
$2.32+1.75%vs prev close - 10.13Pre-market26.10.13 20:09
●●●●●●●● ●●●●● ●●●●●●
Alaunos Therapeutics has officially completed its acquisition of Velaris Therapeutics. This strategic move is expected to expand the company's pipeline and operational capabilities.…more
$2.32+1.75%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report